Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Monjuvi
Pharma
Incyte eyes label expansion for Monjuvi after phase 3 win
The company looks to file its drug for a follicular lymphoma indication as part of a later-line triple combo therapy by the end of the year.
Zoey Becker
Aug 16, 2024 11:23am
Incyte picks up full Monjuvi rights from MorphoSys for $25M
Feb 6, 2024 9:59am
Novartis eyes MorphoSys buyout: Reuters
Feb 5, 2024 3:39pm
MorphoSys CEO touts Monjuvi's potential despite COVID slowdown
Mar 30, 2021 12:38pm
